Clinical Research Directory
Browse clinical research sites, groups, and studies.
Colorectal Analysis for Signature Cancer Assessment Using Delta-HLD
Sponsor: Epiliquid Holding, Inc
Summary
CASCADE (Colorectal Analysis for Signature Cancer Assessment Using delta-HLD Technology) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, for the detection of colorectal cancer. Epiliquid also integrates a proprietary bioinformatic system capable of identifying, ranking, and selecting tumor-specific methylation biomarkers for different cancer types. In this study, colorectal cancer-specific biomarkers will be evaluated in blood and tissue samples using delta-HLD technology, which enables sensitive and multiplexed detection through PCR. Study results will support the validation of Epiliquid's integrated platform as a minimally invasive and accessible diagnostic solution for colorectal cancer.
Official title: Proof-of-concept Case-control Study for Colorectal Cancer Assessment Using Delta-HLD Technology (CASCADE)
Key Details
Gender
All
Age Range
45 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
600
Start Date
2021-06-30
Completion Date
2026-12
Last Updated
2025-08-29
Healthy Volunteers
No
Conditions
Locations (1)
Epiliquid
Mendoza, Argentina